drugset / Trial / NCT04038853
Vitamin D in Fatty Liver Disease
Phase 4
Completed
360 enrolled
University Hospital Rijeka
Pliva Hrvatska d.o.o. · collabUniversity of Rijeka · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study evaluates the influence of vitamin D in reducing laboratory, elastographic (Fibroscan) and metabolic components of NAFLD. Half of the patients will receive vitamin D (Plivit D3) while the other half will receive placebo
Timeline
- Start
- 2015-12-01
- Primary completion
- 2017-02-01
- Completion
- 2019-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcitriol | Small molecule | 1000 iu | Oral |